Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

While gaps persist in workforce retention, infrastructure, and equitable access, the transformation of Nigeria’s health ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

The Dementia Discovery Fund ("DDF"), managed by SV Health Investors, today announced the final closing of its second fund, DDF-2, with $269m in commitments. DDF is the world's largest family of ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

David Rhew, MD, global chief medical officer and VP of ... such as CVS, expanding partnerships have become necessary for their digital progression. Boosted by Microsoft's offerings, CVS intends ...

Pfizer and BioNTech said their alliance aims to develop an "improved" vaccine for shingles, and marks their third partnership in ... easily scalable to support global access," he added.